N/A N=24 Response to Supplement and Placebo in GERD
Gastroesophageal Reflux Disease (GERD) · Heartburn · Dyspepsia
Primary: Safety - Number of Participants Experiencing a Serious Adverse Event — 0; 0; 0; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 The Impact of Renin-angiotensin System on Brain Activation During Hypoglycaemia in Healthy Men, a PET Study
Hypoglycemia · Cognitive Impairment
Primary: Cerebral Activation During Hypoglycaemia — 4.85; 4.55 Z score
Phase 2 N=31 Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant
DS Stage I Plasma Cell Myeloma · DS Stage II Plasma Cell Myeloma · DS Stage III Plasma Cell Myeloma
Primary: Toxicity as Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v3.0 — 0 Participants
Phase 3 N=637 Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents
Rheumatoid Arthritis
Primary: Core Study: Percentage of Participants Achieving an American College of Rheumatology Response 20 (ACR20) at Week 24 — 35.2; 35.2; 19.6 Percentage of Participants…
Phase 4 N=29 A Pilot Study of Early Postpartum Intrauterine Contraception
Unplanned Pregnancy
Primary: IUD Expulsion — 11 Participants
Phase 2 N=58 Pre-Exposure Prophylaxis in YMSM
HIV
Primary: Actual Number of Study Visits Completed by 24 Weeks — 3.5927; 4.6263; 4.6374 Visits — p=0.6983
Phase 3 N=36 Bosentan in Children With Pulmonary Arterial Hypertension Extension Study
Pulmonary Arterial Hypertension
Primary: Change From Baseline to End of Study (EOS) in Height for Age. — -0.8; 0.32; -0.64; -0.74 Z-score
Phase 1 N=23 A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects
Pharmacodynamics · Healthy Subjects
Primary: Pharmacodynamics of AZD9977 Assessed Per Sodium/Potassium Ratio in Urine in Eplerenone Treatment Versus a Combination Treatment of Eplerenone and AZD9977. — -0.545…
Phase 4 N=404 Perioperative Cognitive Function - Dexmedetomidine and Cognitive Reserve
Postoperative Delirium · PD · Postoperative Cognitive Dysfunction
Primary: Delirium Battery — 23; 23; 6; 8 Participants
Phase 3 N=50 A Comparison of Targinact vs. Oxycodone on Gut Function After Colorectal Surgery
Postoperative Pain · Postoperative Nausea and Vomiting
Primary: Prevalence of Postoperative Gut Dysfunction — 13; 15 Participants — p=0.264
Phase 2 N=14 Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting
Blood Transfusion · Endothelial Physiopathology · Nitric Oxide
Primary: Systolic Pulmonary Artery Pressure — 39; 46; 31 mmHg
Phase 3 N=798 Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children
Whole Cell Pertussis · Tetanus · Hepatitis B
Primary: Number of Subjects With Fever >39°C (Rectal Route). — 22; 8; 5; 3 Participants
N/A N=10 Microembolic Signals and Cerebrospinal Fluid Markers of Neuronal Damage After Surgical Aortic Valve Replacement
Aortic Stenosis
Primary: Transcranial Doppler(TCD) Microembolic Signals During Surgical Aortic Valve Replacement Surgery — 354 units on a scale
N/A N=9 Impact of KUVAN® on Gastric Relaxation in Women With Diabetic Gastroparesis.
Gastroparesis
Primary: Gastric Accommodation — 322.22; 402.78; 450.63 ml
Phase 2 N=31 A Pharmacokinetic Study of a Single-Dose of Diazepam Nasal Spray in Adult Epileptic Patients Experiencing a Seizure Episode
Epilepsy
Primary: Pharmacokinetic (PK) Parameter: Maximum Measure Plasma Concentration (Cmax), — 208; 23.9 nanogram/milliliter (ng/mL)